2 天前 - … achieved some success in managing disease progression after the failure of frontline
… for drug resistant disease. Next, we perform a collateral sensitivity screen of a lung cancer …

2 天前 - … After progression on first line systemic therapy with doxorubicin, the patient received
… sensitivity in non-lung ALK rearranged tumours, contrary to experience in lung cancer. …

3 天前 - … The aim of this study is to evaluate the predictive significance of tumor expression
of PD-L1 as well as the number and site of metastasis in non-small cell lung cancer (NSCLC) …

3 天前 - Immunotherapy has made remarkable progress within the past decade, but the role
of B cells in tumor immunity remains unclear. Here, we show that the combination therapy of …

3 天前 - … In addition, during disease progression, we first identified MET D1228N as a potential
mechanism for crizotinib resistance in this patient. This finding provides new insights into …

3 天前 - … , which plays critical roles in the bouts and progression of diseases such as breast
cancer, gastric carcinoma, lung cancer, and brain tumor. Molecular mechanisms and clinical …

3 天前 - … lung cancer (NSCLC) with inferior survival outcomes, we analyzed and compared
survival outcomes among patients with and without baseline presence and early clearance of …

3 天前 - … with oligoprogressive disease in EGFR-mutated non-small cell lung cancer [18,
31, 32]. Our study suggested that primary tumor radiotherapy after disease progression(R PD ) …

4 天前 - Objectives: Lenvatinib was approved for the treatment of patients with radioiodine-refractory
differentiated thyroid cancer (RAI-R DTC) in Europe in 2015 and Canada in 2016. …

4 天前 - … 6/23 (4 females) were diagnosed with PDTC during progression of papillary DTC.
Clinicopathological characteristics are reported in the following table. Patients with de novo …